ARTISAN BIOPHARMA
Advancing new therapies for pediatric cancers, aiming for cure.
Artisan Biopharma –
A for-profit subsidiary of cc-TDI
(LLC and Public Benefit Company)
artisan biopharma
We craft medicines
Our mission is to translate scientific discovery into clinical trial-proven medicines by understanding and proving new disease-specific treatment options for children with cancer. We use R&D to create bespoke childhood cancer medicines that will have a dual purpose in adult indications.
Founded in 2019, Artisan Biopharma consists of a collaborative Team of scientists, pharma-experienced chemists and enterprise level professionals approaching the common goal to make childhood cancer universally survivable.
CURING THE UNCURABLE
Our Mission
Few rare patient populations are as vulnerable and in need of advocacy as children with cancer. Pharmaceutical companies face many disincentives to pursue pediatric oncology therapeutics, including low incidence, unplanned/added costs of conducting pediatric trials, lack of funding for early-stage research, and small markets.
Artisan is leveraging the deep preclinical domain expertise of cc-TDI to reverse the 48+ year drought represented by only 14 primary drug approvals for pediatric cancer. To achieve this goal, we aim to have 5 new compounds reach the clinic annually for children with high risk cancers.
The Children’s Cancer Therapy Development Institute (cc-TDI) has since spent more than a decade devoted to the research of rare, aggressive, and difficult-to-treat pediatric cancers, supported by NIH, foundation level grants and proactive individuals & families.
A new way pediatric oncology drugs are brought to market
24 years in pediatric cancer research
We collaborate with industry and academic Partners.
Inspired Solutions
We redefine medicine
A team of like-minded individuals launched Artisan Biopharma with the aim of using the knowledge and experience of cc—TDI to disrupt the status quo of the pediatric cancer drug development process. Simply said, the Artisan team will curate and accelerate clinical trials to get better treatment options to our children, faster.
ARTISAN BIOPHARMA
Investment Highlights
We address an unmet clinical need for treatment of children with cancer while innovatively addressing the paradox of childhood cancer drug development: while childhood cancers are too rare for venture capital or pharma investment in drug development, our childhood cancer bioPROTAC drug in development for rhabdomyosarcoma has a secondary market for adult-onset diabetes. Similarly, our antibody-drug conjugate for the childhood brain tumors Diffuse Intrinsic Pontine Glioma (DIPG) and glioblastoma has a secondary market in adult glioblastoma and other cancer indications.
Validated Partners
We collaborate with industry and academic Partners in sarcoma, brain tumors, and other pediatric cancer research, as well as prominent UK Universities.
De-Risked Platform
Leveraging clinically proven mRNA delivery (COVID learnings) and established nanobody screening libraries.